Introduction
Due to its high prevalence and associated morbidity and mortality, influenza is a major public health concern that affects millions of Canadians every year. It is estimated that every year between 2000 and 8000 Canadians die of influenza or its complications, depending on the seasonal severity. 1 Although influenza affects all age groups, influenza infection is most common in children, as between 15% and 42% of preschool-and school-aged children each season may experience influenza. 2 In addition, school-aged children spread influenza to other schoolchildren, family members, and members of the community. 3, 4 However, many children do not receive vaccinations or do not follow the recommended dose regimen, 4, [5] [6] [7] despite the fact that immunization is one of the most effective and cost-effective ways to protect against influenza. There are currently two types of influenza vaccines available in Canada: intranasal live attenuated influenza vaccine, trivalent (LAIV; FLUMIST ® ; MedImmune, Gaithersburg, MD) and injectable trivalent inactivated influenza vaccine (TIV). Although LAIV is indicated for the prevention of influenza in Canadians aged between 2 and 59 years old, 8 the Canadian National Advisory Committee on Immunization recently stated that for healthy children and adolescents aged between 2 and 17 years old, " [a] vailable data indicates that LAIV would be preferred over TIV in this population, although the [National Advisory Committee on Immunization] recognizes that other programmatic considerations will impact the implementation of this recommendation in publicly funded programs." 9 To help inform decision makers about the relative value of LAIV, the study objective was to determine the costeffectiveness of LAIV and TIV in healthy Canadian children and adolescents.
Methods

Study overview
A cost-effectiveness model 10 comparing LAIV and TIV in children aged 24-59 months was supplemented by primary (ie, a survey of 144 Canadian physicians) and secondary (eg, literature) data to model three age cohorts of Canadian children: 2-5 years of age, 6-9 years of age, and 10-17 years of age. Extrapolation of these results to healthy children aged 2-17 years old was conducted using Canadian age distribution statistics from Statistics Canada. 11 In the absence of dominance (ie, one alternative being less costly and more effective than the other alternative), the results were reported in terms of incremental cost per quality-adjusted life year (QALY) gained, as per the recommendations of the current Canadian guidelines for economic evaluations. 12 Univariate and probabilistic analyses were conducted, and both a Ministry of Health perspective and a societal perspective were considered. All costs were expressed in 2010 dollars and the model was built in Microsoft ® Excel (1997) (1998) (1999) (2000) (2001) (2002) (2003) Microsoft Excel, Microsoft Corporation, Redmond, WA).
Model structure and time horizon
As shown in Figure 1 , children can develop vaccine-related adverse events (AEs) following the administration of LAIV or TIV (eg, fever, runny nose, sore arm). In both cases (no AEs or AEs), two outcomes are possible: no influenza or influenza. Influenza can present as either uncomplicated influenza, influenza with acute otitis media (AOM), influenza with lower respiratory infections (LRI), or influenza with AOM and LRI. Children could survive or die following influenza. As children are vaccinated against influenza with either LAIV or TIV, the basic structure of the two treatment arms was similar. A 12-month time horizon was used in the analysis to capture all costs and outcomes associated with an influenza episode.
Vaccine effectiveness
The efficacy of LAIV and TIV was taken from the reanalysis 10 (and MedImmune LLC, data on file, 2007) of a large head-to-head double-blind randomized trial comparing LAIV and TIV in children aged 6-59 months (the Belshe et al trial), 13 to determine the relative efficacy of LAIV in children aged 24-59 months. Results indicated that among those children aged 24-59 months who developed influenza (4.90% and 10.46% of those vaccinated with LAIV and TIV, respectively), the vast majority had uncomplicated influenza (4.30% in the LAIV group and 8.64% in the TIV group), while a small proportion experienced influenza with AOM (0.23% and 1.00% for the LAIV and TIV arms, respectively), or influenza with LRI (0.37% and 0.82% for the LAIV and TIV arms, respectively) 10 (and MedImmune LLC, 2007). Since recent evidence surrounding LAIV suggests there is no difference in efficacy in healthy children by age or circulating influenza subtype, 14, 15 it was assumed that the relative efficacy of LAIV compared with TIV was similar in the three age groups.
Since the severity of influenza may change depending on age group and in the absence of Canadian primary and secondary data for children aged older than 5 years, 144 Canadian physicians were surveyed to estimate the breakdown of influenza by age group in terms of: (1) uncomplicated influenza, (2) influenza with AOM, (3) influenza with LRI and (4) influenza with AOM and LRI. As a reference point, physicians were provided with the values used by Belshe et al 13 for children aged 2-5 years old (ie, 82%-88% of all influenza episodes were uncomplicated influenza). Physicians were asked to validate these estimates for children aged 2-5 years old and to provide an estimate for the two other age groups (ie, 6-9 years of age and 10-17 years of age). The resulting influenza breakdown was applied to the overall efficacy of LAIV and TIV for each age group assuming no differences in severity of influenza between arms, as shown in Table 1 . The probabilities of vaccine-related AEs (medically significant wheezing [MSW] occurring within 42 days following vaccination, injection-site reactions, and reactogenicity events occurring within 10 days following submit your manuscript | www.dovepress.com Dovepress Dovepress vaccination) and influenza-related mortality (0.0001% for uncomplicated influenza and influenza with AOM, and 0.0025% for influenza + LRI and influenza + AOM + LRI) were taken from the re-analysis 10 (and MedImmune LLC, 2007) of the trial conducted by Belshe et al. 13 These results were adjusted for the two other age groups, assuming that the rate of influenza in children older than 5 years of age was similar between treatment arms. Contrary to Luce et al, 10 AEs related to the injection site only were assumed to be 0 for LAIV (vs 5.35% in Luce et al 10 ) , while AEs related to runny or stuffy nose only were set at 0 for TIV (vs 7.5% in Luce et al 10 ). Since MSW is unlikely to occur in older children, we assumed a zero probability of MSW in children aged 10-17 years old. To reflect that the AEs related to the influenza vaccination decrease with age, injection site events for older children were adjusted based on the study conducted by Prosser et al (Table 1) . 16 For example, Prosser et al 16 assumed that the probability of an injection-site reaction decreased from 0.0025 in children aged 2-5 years old to 0.001 in children aged 5-11 years old, and to 0.0003 in children aged 12-17 years old.
Calculations of QALYs
On a scale from 0 (death) to 1 (perfect health), the model attributes utilities of 0.558 to uncomplicated and complicated influenza, 17 0.851 to MSW, 18 and 0.9333 to noninfluenza or to a nonwheezing period, 19 as per Luce et al. 10 The average number of symptom days was derived from the Belshe et al trial 13 (4.03 for uncomplicated influenza, 11.06 for complicated influenza, and 12.78 for MSW), and this information was applied across the three age groups. To calculate QALYs, utilities were weighted by time spent in health states (eg, number of symptom days). 20 As an illustration, the average annual QALYs associated with influenza were calculated as: Notes: *Defined as injection site only (assumed 0 for LAIV)
+ injection site and runny/stuffy nose + injection site and other reactogenicity + injection site, runny/stuffy nose, and other reactogenicity; † defined as runny/stuffy nose only (assumed 0 for TIV) + other reactogenicity only + runny/stuffy nose and other.
Abbreviations: LAIV, intranasal live attenuated influenza vaccine; TIV, injectable trivalent inactivated influenza vaccine; AOM, acute otitis media; LRI, lower respiratory infections.
without influenza) × 361.22 days (average number of days with no influenza)]. Similar calculations were used to calculate the QALYs associated with MSW and complicated influenza.
Resource utilization and unit costs
The model considers resource utilization and costs incurred by the Ministry of Health (eg, vaccine-, AE-, and influenzarelated costs). To reflect a societal perspective, indirect costs incurred by parents (eg, over-the-counter medications, transportation costs, and the cost of lost days of work or usual activities performed by parents due to the children's vaccination or influenza episodes) were also analyzed. The probabilities of off ice visits were calculated by multiplying the rates of MSW, as well as the rates of complicated and uncomplicated influenza (as given in Table 1 ) by the corresponding number of physician visits, which were derived from the physician survey ( Table 2 ). The probabilities of influenza-related hospitalizations for LAIV and TIV across each age group were calculated using Canadian data from the Sebastian et al study, 21 and were applied to the Belshe et al trial (MedImmune, 2007) . 13 In the absence of Canadian data, the probability that children aged 2-5 years old would undergo hospitalizations following MSW was taken from Luce et al 10 and applied to the other age groups, assuming equal rates between treatment arms. Furthermore, the length of stay associated with hospitalizations, the proportion of emergency room (ER) visits due to influenza or MSW, as well as medical management of influenza and MSW, were also taken from Luce et al's 10 study. To calculate the amount of time lost by caregivers, our panel of physicians was asked to estimate the proportion of medical visits across each age group in which at least one parent accompanied their child (ie, 100% of the time for the children aged 2-9 years old and 75% of the time for the older age group), as well as the percentage of office visits in which the children attended strictly to receive the influenza vaccine (ie, 32% of the time). The model assumed that only one parent would accompany the children, and it was identified that the parent who always attended these consultations was the mother. Canadian data were used to identify the proportion of mothers who were employed full-time (54%), part-time (19%), and to calculate the average transportation costs spent to travel to the physician's office (CAD$1.32). [22] [23] [24] Time lost from work (full time worker) or from usual activities (mother not working) due to vaccination was only applied when the purpose of the visit was only to receive an influenza vaccination as determined by the physicians. Time lost due to an influenza episode was based on the number of febrile submit your manuscript | www.dovepress.com days observed in the Belshe et al trial, 13 which was assumed to be similar between treatment arms and older age groups (ie, from 3.00 days to uncomplicated influenza to 3.52 days for influenza + AOM).
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The cost per dose of LAIV (CAD$14.00) was provided by the manufacturer, while the weighted average cost of a dose of TIV was calculated at CAD$9.59 based on IMS Drugstore and Hospital sales for January 2010 (data on file, AstraZeneca Canada). Costs related to the administration of the vaccine were taken from Sanders et al, 25 while other costs were derived from public sources in Ontario or Canada (Table 3) . For children with previous vaccinations (37% and 42% for children aged 2-5 and 6-9 years old, respectively, as per the results of the physician survey), it was assumed that one dose of LAIV or TIV would be administered. It was also assumed that two doses of the vaccine were to be given to all children with no previous influenza vaccination. As per the guidelines of the Canadian Paediatric Society, children aged 9 years or older were assumed to receive one dose of the vaccine. 26 
Incremental cost-effectiveness analyses
The base case scenario evaluates the cost-effectiveness of vaccinating children for the first time with LAIV as opposed to TIV, taking into account that approximately 63% of children aged 2-5 years old have never been vaccinated for influenza, as per the physician survey. Three age groups were modeled and the results were extrapolated to healthy children aged between 2 and 17 years old using Statistics Canada data on Canadian age distribution. 11 As of July 1, 2008, out of 6,206,814 Canadian children aged between 2 and 17 years old, 23% were aged 2-5 years old (1, 417, 525) and 23% were aged 6-9 years old (1,442,144 ). Children aged 10-17 years old accounted for 54% of this population (3, 347, 145) . These percentages were used to calculate the expected costs and benefits of vaccinating children aged 2-17 years old. The base case analysis did not include any benefits derived from the prevention of influenza transmission within a household resulting from vaccinating children against influenza.
In a secondary analysis, we evaluated the impact of including secondary wild-type influenza virus transmission among household members. In this scenario, it was assumed that 18% of contacts per influenza case contracted influenza. 31 Time lost by each parent (either from work or from performing their usual daily activities) due to influenza transmitted from the child was also considered in this scenario.
Univariate and probabilistic sensitivity analyses
Variables tested in univariate sensitivity analyses included, but were not limited to, the relative risk reduction of LAIV versus TIV (from 70% to 30%; base case: 54%); the price of TIV vaccine (from CAD $9.59 to $7); the percentage of children requiring two doses (ranging from 0% to 100%); and all unit costs (±20% of the base case costs). Probabilistic analyses in which all parameters for LAIV and TIV were varied simultaneously according to specified distributions were conducted using Monte Carlo techniques. According to good modeling practices, 32 beta distributions were used to represent the uncertainty associated with probabilities (eg, the probability of developing MSW) or utilities. Gamma distributions and trimmed normal distributions were used for the cost and length of stay data, respectively. Both the beta and gamma distributions were fitted by the method of moments. 32 Table 4 presents the characteristics 
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of the distributions used in the probabilistic sensitivity analyses for the main study parameters. When measures of dispersion were not available, the following conventions were used to fit the distributions used in the probabilistic sensitivity analyses. Standard errors were assumed to be 20% of the mean values associated with proportions (eg, influenza) and unit costs other than hospitalization costs (eg, drug costs). Standard errors were assumed to be 100% of the mean hospitalization costs and 10% for the utility data. A total of 1000 simulations were conducted and the uncertainty associated with the parameters was represented using cost-effectiveness acceptability curves. 32 It should be noted that the uncertainty associated with the effectiveness of the vaccines was not incorporated by fitting a distribution to the relative effectiveness of LAIV when compared with TIV, but rather by varying the effectiveness of each vaccine. As such, different distributions were assigned to LAIV and TIV (Table 4) . Table 5 Costs results* 
Results
Due to the increased efficacy of LAIV compared with TIV in preventing influenza in children, the additional cost of LAIV was offset by the decrease in costs associated with AE management, outpatient physician visits, ER visits, and hospitalizations for all age groups (Table 5) . Indirect costs were also reduced with LAIV. In terms of outcomes (Table 6) , vaccinating 100,000 healthy children aged 2-17 years old with LAIV instead of TIV was estimated to gain 34 QALYs. Vaccinating these children was also found to prevent around 5500 cases of influenza, 10,000 physician visits, 1000 ER visits, and 17,500 days lost of which 11,500 were the equivalent of full -time days lost from work (Table 6 ). When a reduction in secondary transmission of the wild-type virus to household contacts was modeled across all age groups, LAIV was associated with additional cost savings when compared to TIV. From a societal perspective, the savings increased from CAD$39.03 to CAD$56.77 for children aged 2-5 years old, from CAD$33.03 to CAD$50.77 for children aged 6-9 years old, and from CAD$34.75 to CAD$52.48 for children aged 10-17 years old. The results of other univariate sensitivity analyses indicated that these results were robust against changes in the price differential between LAIV and TIV, and robust against changes in relative risk reductions associated with LAIV versus TIV. The results also held up against other model assumptions (Figure 2) .
The results of the probabilistic sensitivity analyses are shown in Figure 3 , which presents the cost-effectiveness acceptability curves. Results indicated that if society was willing to pay CAD$50,000 per QALY (societal perspective), the probability of LAIV being cost-effective was 0.96 for children aged 2-5 years old, 0.92 for children aged 6-9 years old, and 0.94 for children aged 10-17 years old. At CAD$100,000 per QALY, these probabilities increased to close to 1 for all age groups. Similarly, from a Ministry of Health perspective, the probability of LAIV being costeffective for all direct health care costs was almost 1 for all age groups at commonly accepted thresholds (Figure 3 ).
Discussion
Similar to the previous US cost-effectiveness analysis of LAIV versus TIV administration in children aged 2-5 years old, 10 the results of this study indicated that LAIV was the dominant influenza vaccination strategy used in healthy children aged 2-5 years old from both a societal and a Ministry of Health perspective. LAIV was also found to be the dominant strategy for the other two age groups and for Canadian children aged 2-17 years old, despite the fact that conservative assumptions were used when extrapolating the results observed in the Belshe et al trial 13 to an older population of healthy children. When all model parameters were simultaneously varied, the results of the probabilistic analyses indicated that the probability of LAIV being cost-effective in comparison to TIV was almost one at commonly accepted thresholds (eg, CAD$50,000 and CAD$100,000 per QALY gained). When secondary transmission was modeled, LAIV provided additional benefits at a lower cost. Although we did not include this scenario as our base case analysis to provide a more conservative estimated benefit, recent Canadian data suggest that these protective effects may be even larger than those anticipated in our analyses. 33 Similarly, other potential benefits of LAIV were not modeled, such as increased vaccination compliance due to LAIV needle-free administration, 34 substantial efficacy following a single dose in previously unvaccinated young children, 35, 36 and an approximate efficacy rate of 60% through a second influenza season without revaccination. 37 Several limitations were associated with this study. In comparing LAIV and TIV, the study relied on a large randomized controlled trial of primarily healthy children and it is not known how these results apply to children with asthma or wheezing. However, it is very unlikely that the results would change significantly given that similar relative efficacy results were observed in young children with a history of recurrent respiratory tract illnesses and in older children and adolescents with asthma. 38, 39 We also assumed that the relative efficacy of LAIV compared with TIV was similar across age groups. Although this assumption was supported for LAIV, as per recent analyses of LAIV evidence, 14, 15 we assumed the same for TIV in a conservative approach.
In the absence of head-to-head trials in older healthy children, data regarding the rates of other outcomes following submit your manuscript | www.dovepress.com Dovepress Dovepress influenza in children aged 24-59 months old were sometimes used to model the two other age groups. To mitigate the impact of this assumption, we always assumed equality between the two treatments. In addition, sensitivity analyses decreasing the relative efficacy of LAIV when compared to TIV in all age groups indicated that LAIV was still the dominant strategy (from a societal perspective) even when the efficacy rate was reduced to 30% (as compared with 54%).
Noncompliance to vaccination schedules for children aged less than 9 years old was not modeled, although this is a frequent problem in real life. However, this assumption should not adversely affect the relative efficacy of LAIV compared with TIV, as LAIV has shown high efficacy following a single dose in previously unvaccinated children.
15,36
Although we did not include secondary transmission of influenza in the base case analysis, LAIV was found to 
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provide additional benefits at a lower cost when secondary transmission was modeled; however, the model structure used in our analysis (ie, the decision tree) cannot fully deal with the spread of disease between individuals. The use of transmission models characterizing the population as being susceptible to infection, being infected, or being infectious to others is an important avenue of research to evaluate the cost-effectiveness of influenza vaccines. We did not model a "no vaccination" strategy; rather, we used data from a headto-head trial comparing two vaccines. It should also be noted that this trial was conducted during the 2004-2005 influenza season, which was a mild to moderate influenza season. As such, the results may not be generalizable to severe influenza seasons. In the absence of pediatric utility data, we followed the approach used by Luce et al, 10 which was to use adult utility values as proxy. Although utility data derived from a pediatric population is the preferred option when modeling populations of children and adolescents, changing the utility values associated with no influenza, influenza, or MSW should not affect the overall conclusion (eg, more QALYs generated with LAIV).
Finally, a value of information analysis was not conducted to determine if there would be value in conducting additional research to reduce the remaining uncertainty associated with the results. However, this situation is unlikely since the results of the probabilistic sensitivity analyses indicated that the probability of LAIV being more cost-effective than TIV was almost one at commonly cited thresholds. In addition, the results of the sensitivity analyses indicated that LAIV was still cost saving, even when the relative risk reduction of LAIV compared with TIV was decreased from 70% to 30% (Figure 2 ).
Despite these limitations, this study also had several strengths. First, the study used data from a large head-to-head randomized trial comparing LAIV and TIV in children aged 2-5 years old and conservative assumptions were used when it was necessary to extrapolate the results to older children. Second, we surveyed 144 Canadian physicians to estimate several key variables not available from the literature (eg, number of physician visits). The large number of physicians answering the survey and the variety of their geographical locations provided a good representation of the treatment of influenza in Canadian primary care practices. Finally, to take into account the uncertainty associated with key model parameters, we conducted a probabilistic analysis as well as several univariate sensitivity analyses; in all scenarios, LAIV was still the dominant strategy.
In conclusion, vaccinating Canadian children between the ages of 2-17 years old with LAIV instead of TIV was found to be the dominant strategy from both a societal and a Ministry of Health perspective.
